GB2284210A - Translational enhancer DNA from light chain of kinesin - Google Patents

Translational enhancer DNA from light chain of kinesin Download PDF

Info

Publication number
GB2284210A
GB2284210A GB9424130A GB9424130A GB2284210A GB 2284210 A GB2284210 A GB 2284210A GB 9424130 A GB9424130 A GB 9424130A GB 9424130 A GB9424130 A GB 9424130A GB 2284210 A GB2284210 A GB 2284210A
Authority
GB
United Kingdom
Prior art keywords
dna
kinesin
protein
gene
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9424130A
Other versions
GB9424130D0 (en
GB2284210B (en
Inventor
Yuti Luis Alberto Chernajovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939324394A external-priority patent/GB9324394D0/en
Priority claimed from GB9417597A external-priority patent/GB9417597D0/en
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Publication of GB9424130D0 publication Critical patent/GB9424130D0/en
Publication of GB2284210A publication Critical patent/GB2284210A/en
Application granted granted Critical
Publication of GB2284210B publication Critical patent/GB2284210B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

Isolated DNA, which expresses the light ( beta -)chain of kinesin contains at its 5'-end a region of DNA of high secondary structure which provides a strong enhancer of translation, which in the human kinesin gene it forms a double hairpin loop. The secondary structure, optionally with flanking sequence, is claimed as isolated DNA. Constructs in which the DNA serves is an enhancer for expression of foreign DNA are described.

Description

TRANSLATIONAL ENHANCER DNA Background of the invention 1. Field of the invention The invention relates to DNA useful as an enhancer of translation of nucleic acids in the production of proteins therefrom.
2. Description of the related art Kinesins are molecular motor proteins implicated in the intracellular transport of organelles in brain cells and in the movement of chromosomes along microtubules during cell division. In sea urchin and mammalian cells, kinesins have been characterized as tetrameric proteins. Two subunits are the two heavy chains (a chains) of a relative molecular mass of approximately 120 kDa and two light chains (p chains) of approximately 70 kDa. Intracellular organelles move along microtubules inside the cell by attaching to the tetrameric aalP P kinesin molecular motor.The a chains provide the tubulin binding site and the ATPase domain, whereas the p chains are responsible for the specific attachment of the organelle to be moved by the kinesin tetramer.
At present three rat brain kinesin p chain cDNAs have been cloned, (J.L. Cyr et al., Proc. Natl. Acad. Sci. USA 88 10114-10118) and a partial cDNA sequence (named EST00761) of human brain origin has been entered on the EMBL database as a result of the human genome sequencing work reported by M. D. Adams et al., (Nature 355, 632-634 (1992)). The three rat cDNAs are the product of one gene spliced differentially at the 3'end, producing different COOH terminal ends in the protein and thereby predicting three different isoforms of light chain, designated "A", "B" and "C". This mechanism seems to confer the kinesin specificity for organelle binding.
An unpublished human p-kinesin cDNA sequence of length 2309 bp has been entered on the EMBL database under Accession No. LO4733 by L.B. Lachman et al. and published as Cabeza-Arveliz et al., DNA Cell Biol. 12, 881-892, 1993.
Summarv of the invention It has now been found that the p-chain kinesin genomic DNA contains a region of DNA of high secondary structure which provides a strong enhancer of translation (not to be confused with an enhancer of promotion). In the human kinesin, the secondary structure lies within the first exon ofthe gene, which provides the 5'-untranslated end ofthe mRNA.
It takes the form of a double hairpin loop which is illustrated for the mRNA in Figure 4 of the drawings.
The invention includes isolated DNA from part of the plight chain gene of a kinesin as well as various constructs in which this DNA serves as a translational enhancer.
Thus, in one aspect, it includes isolated DNA from the 5'-end of the allelic gene which expresses the plight chain of a kinesin, said DNA being a translational enhancer and comprising a region of high secondary structure, capable of being represented as a hairpin loop; or a translation-enhancing substitution or deletion mutant thereof.
The isolated DNA thus includes the secondary structure region and optionally additional DNA to the 5'- or 3'-end thereof, which may be the DNA native to the same kinesin gene. Thus, the isolated DNA can include any or all such DNA extending in the 5'-direction back to the 5'-end ofthe light chain gene. Thus, it may include part or all of the promoter region which extends upstream of the mRNA start site. It may include part or all of the first intron (which lies between the first exon coding for untranslated mRNA and the second exon coding for the N-terminal region ofthe p-kinesin protein).
Since the p-kinesin promoter is not particularly strong, the invention can be put to better use by linking the translational enhancer DNA to a strong eukaryotic promoter.
Thus, in another aspect the invention provides a construct for enhanced expression of nonp-kinesin DNA encoding a protein, comprising (1) a eukaryotic promoter, which is preferably a foreign promoter stronger than that of the native p-kinesin gene, (2) downstream thereof, translational enhancer DNA ofthe invention and (3), downstream of the enhancer, foreign DNA i.e. coding for a protein other than p-kinesin.
The p-kinesin gene also contains within the first exon, upstream ofthe secondary structure, a region which codes for a small protein (12 aa long). This region appears designed to facilitate the binding of a ribosome to the mRNA somewhat downstream thereof. Accordingly, the first exon of the p-kinesin gene appears to provide an internal entry ribosome site (IRES). Such a site enables the mRNA to be translated independently of any translation initiation sites. Effectively it can provide a way of enabling two genes to be transcribed using a single promoter. Thus, in another aspect the invention provides a construct for expression of two protein-coding DNAs which comprises (1) a eukaryotic promoter, (2) downstream of the promoter, first foreign DNA, i.e.DNA coding for a first protein other than p-kinesin and which lacks a termination of transcription signal, (3) downstream of the first foreign DNA, DNA of the invention, further comprising the small protein-coding region, thus serving as an internal ribosome entry site (IRES) and for enhancement of translation and (4) downstream of the IRES-translational enhancer DNA, second foreign DNA, i.e. DNA coding for a second protein other than p-kinesin and which is distanced downstream from the IRES-translational enhancer DNA so as to permit translation of mRNA from the IRES.
Brief description of the drawings Figure 1 is a restriction enzyme map of a phage 2.1B isolated from genomic DNA of human p-kinesin and of a cloned fragment thereof inserted in a plasmid E/S; Figure 2 shows the DNA sequence of a 838 kb length of DNA at the 5'-end of the human p-kinesin gene; Figure 3 shows a DNA sequence comparison of human kinesin and rat cDNAs including a sequence corresponding to part of the first exon of the human genomic DNA which codes for a 12aa peptide and further including the beginning of the coding sequence; Figure 4 shows a region of high secondary structure (translational enhancer) within the human kinesin mRNA corresponding to another part of the first exon of the genomic DNA; Figure 5 shows the insertion of a portion of the sequence of Figure 2 including the enhancer into a plasmid containing a CAT reporter gene;; Figures 6 and 7 show schematically two DNA constructs incorporating the translational enhancer DNA of the invention.
Figure 8 shows plots of radiolabelled protein translated in vitro from human p- kinesin cRNA in a rabbit recticulocyte lysate assay; Figure 9 shows plots of CAT activity against amounts of DNA transfected winto COS cells when the CAT gene is expressed from two plasmids differing only in that one has a human p-kinesin hairpin loop fragment between the promoter and the CAT gene.
Description of the preferred embodiments Figure 2 shows the DNA sequence (838 nucleotides) of the 5' flanking, exon and intron ofthe human p-kinesin gene. Numbers indicate position of the nucleotide after the initiation site oftranscription of mRNA (+1) or upstream of it (negative numbers). The first exon, from 1 to 253, is in italics and underlined. Restriction enzyme sites are underlined and indicated. Putative TATA box, SPl and cAMP-modulated transcription factor (CREB) binding sites are in shaded areas.
As will be seen, the promoter region runs from nucleotide -1 to at least -121 as shown by the identified transcription factor binding sites normally present in eukaryotic promoters. At the other end of the sequence, nucleotides 254 onwards are part of a first intron region thought to be more than 9kb long.
Figure 4 indicates the high degree of secondary structure responsible for the enhancer function of a DNA of the invention which comes from the human p-kinesin gene.
The Figure is drawn up in terms of mRNA bases, but is readily transposable to genomic or cDNA by substituting thymines (T) for uracils (U) throughout. Thus, the left-hand end of the mRNA beginning CUGCUG... transposes to nucleotides CTGCTG... at 132 to 137 in Figure 2, while the right-hand end of the mRNA ending ...AGGCG(A) is present at nucleotides 249-253 of Figure 2. The A nucleotide at the end of the RNA is that of the putative start codon at the beginning of the second exon and therefore does not appear in Figure 2.
The translational enhancer region shown has a potential double hairpin loop, one straight loop extending from the 5'-end, from nucleotide 132 to 176 and the second a branched loop, from nucleotides 177 to 253. This second loop is therefore 76 nucleotides long. Since, however, the rat p-kinesin cDNA sequence is 67 nucleotides shorter than the human within the region ofthe second loop, it may reasonably be assumed that most ofthe 76-long second loop is missing in the rat DNA. Since, further, the p-kinesin gene is well expressed in rats, the reasonable probability is that only the first loop is necessary for translational enhancement. Thus, it is believed that the core area of high secondary structure necessary for a translational enhancer is that of the first loop referred to.
It will be appreciated that the area of high secondary structure for p-kinesin will differ somewhat from one creature to another and that the invention includes sufficient of the area to act as a translational enhancer regardless from which mammal, animal or other being it is derived or to which it approximates.
Excessive lengths of enhancer can be trimmed back if desired, e.g. using the Bal3 1 enzyme or the polymerase chain reaction could be used to generate any desired shorter length. Additional lengths of DNA, whether native to p-kinesin or not, can be added to the 3'- or 5'-end. Preferably native DNA comprises from 1 to 100 base pairs of 5'- or 3'flanking genomic DNA.
It will be appreciated that the secondary structure can be altered in minor respects by substitution of DNA bases, especially in those regions which are not self-paired and especially in those regions which are not self-paired and especially in the downstream (3'- part) of the first hairpin loop and anywhere within the second hairpin loop. Especially, up to 10% of the DNA bases in the loop may be varied and a few deletions, typically not more than four, may alternatively or additionally be made. Such mutations must not be so drastic as to affect the enhancer function.
The p-kinesin mRNA contains a short open-reading frame that is conserved between rat and man: see Figure 3. This open reading frame does not contain upstream a consensus ribosomal binding site. It is thought that such short open reading frame is of advantage to help the ribosome slide to a stronger internal consensus ribosomal site, because the first AUG codon lies in an unfavourable context for initiation. This ORF is believed useful to impart to the region an internal ribosome entry site (IRES) function.
IRES functions have been found in other genes, but mainly in viruses, e.g. HIV, EMCV or poliovirus, and are regarded as rare in animal genes.
Incidentally, the human ss-kinesin sequence in Figure 3 differs from that of the corresponding cDNA sequence in the EMBL database by having a cytidine (C) residue at position 124, instead of an adenine (A).
In the constructs of the invention the p-kinesin promoter is preferably replaced or preceded by a stronger eukaryotic promoter such as from Epstein-Barr Virus, SV40, a long terminal repeat (LTR) of a retrovirus or a cytomelagovirus (CMV) or it may be an inducible promoter such as metallothionein.
The distances between promoter and enhancer (on the 5'-side of the enhancer) and enhancer and start codon of the foreign gene (on the 3'-side of the enhancer) are believed not to be critical to the invention. The same goes for distances between promoter and start codon ofthe first foreign gene and between enhancer and start codon ofthe second foreign gene, in the case of the IRES constructs of the invention. Indeed, on the 3'-side of the enhancer, the first intron region in the p-kinesin gene has a length of about 9 kilobase pairs, so separations of up to 9 kbp at least are likely to be operable. In the Examples, the distance is about 150 bp. Simple further experiment to determine the precise minimum distance is easily accomplished by the person skilled in the art.
Any foreign genes can be used in the constructs of this invention but proteins composed oftwo polypeptide subunits (such as antibodies) are of particular interest to be used in the IRES constructs due to the efficiency of expression from a single promoter and one mRNA molecule.
The following Examples illustrate the invention. All plasmids referred to were cloned and maintained in E. coli DHSa cells, a well known strain. Nucleotide nomenclature is that of Figure 2.
EXAMPLE 1 A human placental genomic DNA library, obtained from Clontech, was cloned in the X EMBL3 phage vector. Thirty plates (15 cm in diameter) were plated with 20,000 phages each. After transfer to nylon membranes and crosslinking with u.v. light the filters were probed with the full length cDNA (2.4 kb) of human kinesin light chain labelled by random priming with calf thymus DNA primers. Salmon sperm and E. coli DNA (at 50 mg/ml each) were used during the prehybridization and hybridization steps. In the first screen, 33 plaques were isolated, from which 11 were true positives and reached the third screening and purification step.These clones were separated into ten groups based on their different restriction fragment patterns with EcoRI and XhoI. The results indicate that the introns of the kinesin gene are large, suggesting that the gene spans more than 90 kb.
A human kinesin chain cDNA (EMBL database accession number LO4733) from a T cell library, named pi-kinesin (i = originating from an immune cell) in pGem3Z was kindly provided by Dr. L. B. Lachman (Dept. of Cell Biology, M. D. Anderson Cancer Center, Houston, Texas, U.S.A. A 5' HindIII fragment ofthe cDNA (0.3 kb) was used as a probe and showed strong hybridisation to three groups of clones. One of these clones, 2.1B, was selected for further work. Its restriction map is shown in Figure 1 (top). "Cos" denote the cohesive ends of the phage. The 4.6 EcoRI- SalI fragment, a restriction map of which is shown in Figure 1 (bottom) wherein the arrow represents the sequence of Figure 2, was further subcloned into plasmid pUC19.The resultant plasmid, denoted "E/S", was sequenced by dideoxy sequencing using T7 DNA polymerase ("Sequenase", USB). Smaller fragments, that hybridized with the 0.3 kb 5' end of the cDNA, were also subcloned. These were a 1.2 kb PstI and a 0.6 kb PstI- SmaI- fragment. The full DNA sequence of the PstI- Smal (0.6 kb) fragment and additional sequence of the 5' genomic flanking sequence is shown in Figure 2. These sequences encompass the promoter area, and the first exon together with part of the first intron of the p-kinesin gene.
The promoter sequence contains several putative transcription factor binding sites including SP1 (GGCGGGG) at nucleotides - 121 to - 115, - 75 to - 69 and - 65 to - 59, CREB (ATGACGTCA) at nucleotides - 46 to - 37 and TATA box (CATTTC) at nucleotides - 32 to - 27 as shown in Figure 2. The first exon is 253 nucleotides long and corresponds to the 5'- untranslated region of the mRNA. Comparison of this DNA region with the recently cloned rat cDNAs showed, as expected, evolutionary divergence at this area, but surprisingly also showed a high degree of homology in an area at nucleotides 93-131 with potential for encoding a small peptide, 12 amino acids long in humans, and 12 amino acids long in rat kinesin light chain isoforms A and C, that is not preceded by a consensus ribosomal binding site (Figure 3). (Note: in this part of the rat cDNA the A and C predicted isoforms are believed identical with the B). This coding region is followed immediately by a GC-rich region capable of forming very stable secondary mRNA structure (AG = -52.2 kcal/mol) as shown in Figure 4.Interestingly only the human mRNA could form a double hairpin structure that requires 122 nucleotides (Nos. 132-253), while the rat rnRNA has only 67 nucleotides in this region, before the kinesin protein start site, and its potential single hairpin structure has lower stability (AG = -23.8 kcal/mol).
In order to show that the region of genomic DNA cloned and sequenced is functional, a reporter plasmid in which the p-kinesin promoter drives transcription of the bacterial chloramphenicol acetyltransferase gene, was constructed as follows. The HSV-tk promoter was removed from the vector pBLCAT9+, L. Klein-Hitpass et al., Nucleic Acids Research 16, 647-663 (1988), using HindIII and BgIII and these ends were blunted with Klenow fragment of DNA polymerase and filled in with dNTPs. The HindIII to Asp718 3.6 kb fragment from the kinesin promoter region was similarly blunted and filled-in and ligated to the CAT gene in this vector with only a small intervening amount of sequence before the CAT gene start codon.The orientation ofthe insert in relation to the CAT gene was assessed by restriction with BamHI and BglII. The plasmid containing the promoter in the right orientation regarding the CAT gene was named "clone 6". Figure 5 shows the resulting plasmid which has the SV40 polyadenylation signal following the CAT gene and also contains an ampicillin resistance marker gene (not shown). "Clone 6" was co-transfected with the selectable marker plasmid pSV2neo into HeLa cells. As a control, the plasmid pBLCAT9+, that has the HSV thymidine kinase (HSV-tk) promoter driving the same bacterial reporter gene, was also co-transfected with pSV2neo. The cells were co-transfected by the calcium phosphate precipitation method with 20 mg of reporter (CAT) gene plasmid and 1 mg of selectable plasmid.After transfection, cells were osmotically shocked with 10% glycerol in DMEM for 4 minutes, washed twice with DMEM serum-free medium, allowed to recover for 48 hours in DMEM with 10% FBS and then trypsinized and diluted 1 to 4 into media containing lmg/ml G418. After two to three weeks, 3040 clones were pooled and grown as a single population of cells. CAT assays were performed as described previously, Y. Chernajovsky petal., Lymphokine Research 9, 199-212 (1990) and C. M. Gorman et al., Molecular and Cellular Biology 2, 1044-1051 (1982).
The expression ofthe CAT gene from the p-kinesin cDNA fragment in the reporter gene plasmid was constitutive, as was the expression from the HSV-tk promoter in the control plasmid. The percentage conversion of chloramphenicol to its acetylated derivative was measured under conditions which gave a linear dependence of conversion on the enzyme concentration. Calibration of the amount of protein extract necessary to obtain a linear CAT assay, showed that cells transfected with "clone 6" gave about the same conversion from 0.2g protein of CAT produced from "clone 6" as from 151lg protein of the control plasmid. This represents 75-fold more CAT activity per unit weight of protein extract than extracts from the pBLCAT9+ transfected cells.
Attempts were made to upregulate the kinesin promoter with second messenger analogs of the cAMP kinase signalling pathway, or protein kinase C. Cholera toxin, forskolin and PMA failed to induce the expression of the reporter genes. On the contrary, they were slightly inhibitory to the p-kinesin promoter and strongly inhibitory for the control (HSV-tk promoter driven) plasmid.
EXAMPLE 2 Similar experiments were performed with human lung fibroblasts and the expression of p-kinesin mRNA measured by Northern blot. No changes in expression were seen after treatment with PMA, dibutyryl cAMP or double stranded RNA.
EXAMPLE 3 Example 1 was repeated but using the neuroblastoma cell line NB 100 obtained from Dr Audrey Evans, Director of Oncology, Children's Hospital, Philadelphia USA. The results were very similar to those of Example 1, with an approximately 75-fold increase in CAT gene expression.
EXAMPLE 4 Example 3 was repeated, substituting NSE (neuron specific enolase) promoter for the HSV-tk promoter of the control plasmid. NSE is a very strong promoter in neuroblastoma cells. Nevertheless, the construct of the invention gave a 75-100 fold increase in expression of the CAT gene.
EXAMPLE 5 This Example shows that the hairpin loop region is responsible for the translational enhancing function of the kinesin DNA of the invention.
The cDNA of kinesin pi was digested at the unique restriction sites OvI (recognising GGCGCC) and SauI (also known as AocI, recognising CTCAGG) at positions 114-119 and 239-244 of Figure 2, respectively in order to remove the hairpin loop structure. (The hairpin structure lies between positions 133 and 255, but it is not necessary to remove the whole of it in order to destroy the self-annealing potential of the RNA). The fragment lacking the hairpin loop region was gel-purified. Its protruding ends were filled in with Klenow fragment of DNA polymerase and dNTPs and religated with T4 DNA ligase.
Plasmids pGEM3z carrying separately (a) the full length pi kinesin cDNA having the hairpin loop excised, were prepared and linearized at the ApaI site located 3' of the translational stop codon.
Capped cRNA was synthesized using T7 RNA polymerase in the presence of the cap analogue 7-methyl GpppG. This cRNA was translated in vitro using a rabbit reticulocyte lysate preparation (Promega Corporation, Madison, Wisconsin, U.S.A.) and 35[S]-methionine, under the conditions recommended by the supplier. After translation, the products were separated on SDS-polyacrylamide gel by the Laemmli method. Gel analysis was performed by treating the gel with 1M sodium salicylate, drying it and subjecting it to autoradiography.
Using dilutions of the cRNA, the efficiency of the cDNAs translation in vitro in rabbit reticulocyte lysate was compared. In Figure 8, 35S methionine (counts per minute) is plotted on the y-axis against ng cRNA in 25y1 volume of translation medium on the x-axis. Figure 8 shows that the cRNA without the hairpin loop structure (HP-), represented by the solid line, is less efficient in translation than cRNA from the full length original cDNA (FL), represented by the broken line. The FL cRNA gave a higher translation rate at low mRNA concentrations.
EXAMPLE4 This Example shows that the hairpin loop region upregulates gene expression in a eukaryotic, transient expression system. This plasmid places the hairpin sequence directly 3' of a 5'-non coding region of a herpes simplex virus (HSV) thymidine kinase (tk) mRNA and includes a HSV-tk promoter which drives a CAT reporter gene. A control plasmid, pBLCAT 9, see Example 1, in which the construct is identical except that the said hairpin loop structure is missing was used for comparison.
A 150bp, NarI- SauI gel-purified fragment, obtained as in Example 5, from the plasmid pSV2MAF, encoding the 5'- human p-kinesin UTR hairpin loop fragment was blunt-ended with Klenow fragment and ligated into SmaI-linearized pUC 18. The resultant plasmid was termed pUC18/HP.
The next step was to remove the HSV tk promoter from pBLCAT 9 plasmid, ligate it to the p-kinesin hairpin loop fragment and then insert this construct into the pBLCAT 9 vector in place of the promoter alone. The tk DNA used is 250 bp long and contains 200 bases of promoter of the 5'-non-coding region followed by 50 bases downstream of the mRNA transcription site. (HSV tk has a promoter region 200 bases long and is followed by 110 bases of DNA which is transcribed into RNA preceding the start codon of the tk gene. In this work, the last 60 bases of the 5'-non-coding DNA were not used).A 250 bp Bgm-SalI, gel-purified fragment from the plasmid pBLCAT 9 encoding the tk promoter was blunt ended with Klenow fragment and ligated into Asp 718- linearized, Klenow fragment-treated pUC 18/HP, so that the p-kinesin hairpin loop fragment was introduced directly 3'-containing of the HSV tk promoter DNA.
This construct was termed pUC 18/Tk/HP. A 375 bp gel-purified BamHI-Hindffi fragment from pUC 1811k/HP encoding the hairpin loop fragment and tk promoter was ligated into BamHI-Hind'III cut, gel-purified pBLCAT 9. This construct was termed pBLCAT/HP and contains the following linear arrangement of DNA (5' to 3'): tk promoter - kinesin HP loop - CAT gene - SV40. The control plasmid pBLCAT 9 has the linear arrangement: tk promoter - CAT - SV40.
Transient transfection of COS cells (monkey kidney fibroblasts expressing the SV40 T-antigen gene : see P. Mellon et al., Cell 27, 279-288 [1981]) by the calcium phosphate precipitation method showed that the 5' kinesin UTR hairpin loop fragment (filled squares) upregulates the expression of the CAT reporter gene by up to fourfold greater than that from a control plasmid without the hairpin loop insert (open squares).
The results are shown in Figure 9, in which units of CAT activity are plotted on the y-axis against amounts of DNA (,ug) used for the transfection on the x-axis. The units of CAT activity were calculated from autoradiograms of standard thin layer chromatography assays of CAT activity and normalised to firefly luciferase activity from the plasmid pSV2L, (de Wet et al. Molecular and Cellular Biology, 7, 725-737 [1987]) used at a constant 5 g per transfection. pUC 18 DNA at 10 and 15 g per transfection was used to maintain the total DNA for each transfection at 25yg.
EXAMPLE 7 This Example confirms that the 5' UTR of the human kinesin gene acts as an IRES. A polycistronic retroviral vector SR10 was constructed and described as follows: A PCR fragment of about 185bp containing the hairpin region of the human kinesin gene was amplified from the plasmid pSV2MAF. The 27mer 3' primer incorporated an NcoI site and had the sequence CTT TAT GTA CAC CAT GGT GGA CAT GTT. The sequence of the 23mer 5' kinesin primer was in part complementary to bases 114-127 and incorporated an EcoRI site. The sequence was ATC AAT TCC GGC GCC CCT AGC TG. The 185bp PCR fragment was restricted with NcoI and EcoRI and ligated into EcoRl/NcoI, gel purified pCITE ECD TNFR.This plasmid has an 800bp fragment encoding for the human p75 TNFR ECD. EcoRllNcoI digestion removes the 592bp IRES cite sequence (Novagen). The resultant plasmid was termed SR9.
The 970bp SalI/EcoRI SR9 fragment containing the human kinesin HP and the human p75 TNF ECD was ligated in to SalI/EcoRI cut pBabe PAGO Neo to give plasmid SR10. pBabe PAGO Neo is a retroviral vector containing a BgmlPvuII, 1.7kb fragment of HSV-TK downstream of the MuLv LTR followed by an SV40 early promoter and neomycin resitance gene. In SR10 the 5' hairpin kinesin UTR/p75TNFR ECD hybrid sequence from SR9 is inserted between the HSV-TK and SV40 early promoter sequence.
Thus, in SR1O, this placed a 170bp fragment encompassing the 5'kinesin UTR directly upstream of a reporter gene encoding the extracellular domain of the human p75 tumor necrosis factor receptor extracellular domain (p75 TNFR ECD) and directly downstream of a sequence encoding the thymidine kinase (TK) which is driven by a LTR MuLv promoter. Since the p75 TNFR reporter gene has no promoter, if expressed in transient transfection experiments, then it can be assumed that the hairpin structure acts as an IRES. The plasmid pBabe PAGO neo ECD which is identical except that the HP fragment is replaced by the known EMC IRES was used as a control. Quantities of p75 TNFR in cell supernatant was measured by ELISA (Bemelmans et al, 1993 J. Immunol.
150, 2007-2017), 2 days after transfection with varying quantities of either SR10 or pBabe Pago neo. The plasmid PSV2LUC (which codes for the luciferase reporter gene) was cotransfected with either test or control plasmid so that expression levels could be normalised for transfection efficiency. In addition, the arbitrary plasmid PUC 18 was included in all transfections to standardise the quantity of DNA transfected.
SR10 and pBabe PAGO neo ECD plasmids were transiently infected into COS cells. 10,ug of either of the latter plasmids was cotransfected with 5yg of PSV2LUC and sufficient PUC18 plasmid to make the total quantity of transfected plasmid up to 25yg.
Transfections were transient and levels of recombinant protein production were measured 48 hours after transfection by ELISA based on 1:100 dilution of a monoclonal antibody 4C8 as a catching antibody and a second 1:5000 dilution of biotinylated polyclonal rabbit IgG anti-TNF-R75 antibody followed by streptavidine peroxidase. Quantities of luciferase in transfected cell protein extracts were determined and used to normalise expression values with respect to transfection efficiency. Antibodies for the ELISA were a gift from Dr M Bemelmans (Bemelmans et al, 1993 J. Immunol. 150 2007-2017.
The results showed that for the SR10 plasmid, recombinant p75 TNFR-ECD protein was produced at high levels confirming that the hairpin fragment does indeed act as an IRES. Levels of production appeared to be up to 10 times greater than those initiated by the EMC IRES of the pBabe PAGO neo plasmid when transfected in equal (10yg) quantities.

Claims (10)

1. Isolated DNA from the 5'-end of the gene which expresses the p-light chain of a kinesin, said DNA being a translational enhancer and comprising a region of high secondary structure, capable of being represented as a hairpin loop; or a translation-enhancing substitution or deletion mutant thereof.
2. DNA according to claim 1 from the portion of said light chain lying between the 5'-end ofthe gene and the 3'-end ofthe first intron.
3. DNA according to claim 1 or 2 wherein the secondary structure consists essentially of the whole of the double hairpin loop or of only the upstream single hairpin loop thereof in the first exon of the human kinesin gene.
4. DNA according to claim 3 wherein the secondary structure consists essentially of nucleotides 132 to 253 of Figure 2.
5. DNA according to claim 2 which comprises, in addition to said secondary structure, from 1 to 100 base pairs of 5'- or 3'-flanking DNA of the light chain.
6. Isolated DNA according to any one of claims 1-5 which further comprises a short open-reading frame predicting a protein of about 12 amino acids upstream of the secondary structure.
7. A construct for enhanced expression of non-p-kinesin DNA encoding a protein, comprising in the order 5' to 3' (1) a eukaryotic promoter, (2) DNA according to any one of claims 1 to 5 for enhancement oftranslation and (3) DNA coding for a protein other than p -kinesin.
8. A construct for expression of two protein coding DNAs which comprises in the order 5' to 3 (1) a eukaryotic promoter, (2) downstream ofthe promoter, DNA coding for a first protein other than p-kinesin and which lacks a transcription termination signal, (3) DNA according to claim 6 as an internal ribosome entry site (IRES) and for enhancement of translation and (4) downstream of the IRES DNA, DNA coding for a second protein other than p-kinesin and which is distanced downstream from the IRES-translational enhancer DNA so as to permit translation of mRNA from the IRES.
9. A construct according to claim 7 or 8 wherein the promoter is one which is stronger than that of the native p-kinesin.
10. A construct according to claim 7, 8 or 9 wherein the protein-coding DNA or second protein coding DNA is distanced from the region of high secondary structure of the enhancer by a length of DNA of up to 9kbp.
GB9424130A 1993-11-26 1994-11-25 Translational enhancer DNA from a kinesin gene Expired - Fee Related GB2284210B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939324394A GB9324394D0 (en) 1993-11-26 1993-11-26 Translational enhancer dna
GB9417597A GB9417597D0 (en) 1994-09-01 1994-09-01 Translation enhancer dna

Publications (3)

Publication Number Publication Date
GB9424130D0 GB9424130D0 (en) 1995-01-18
GB2284210A true GB2284210A (en) 1995-05-31
GB2284210B GB2284210B (en) 1997-11-12

Family

ID=26303925

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9424130A Expired - Fee Related GB2284210B (en) 1993-11-26 1994-11-25 Translational enhancer DNA from a kinesin gene

Country Status (7)

Country Link
US (1) US5723332A (en)
EP (1) EP0730645A1 (en)
JP (1) JPH09505474A (en)
AU (1) AU692196B2 (en)
CA (1) CA2174863A1 (en)
GB (1) GB2284210B (en)
WO (1) WO1995014775A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251609A (en) 1997-02-12 2000-04-26 尤金·Y·查恩 Method and product for analyzing polymers
US6403311B1 (en) 1997-02-12 2002-06-11 Us Genomics Methods of analyzing polymers using ordered label strategies
AU6667798A (en) 1997-02-25 1998-09-09 Q.B.I. Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
FI972293A (en) 1997-05-30 1998-12-01 Joseph Atabekov Methods for co-expression of more than one gene
US6933378B2 (en) 1997-05-30 2005-08-23 Joseph Atabekov Methods for coexpression of more than one gene in eukaryotic cells
US6210896B1 (en) 1998-08-13 2001-04-03 Us Genomics Molecular motors
CN1345792A (en) * 2000-09-22 2002-04-24 上海博德基因开发有限公司 Novel polypeptide-human kinesin light chain 62.92 and polynucleotide for encoding said polypeptide
AU2002227156A1 (en) * 2000-12-01 2002-06-11 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US7668697B2 (en) * 2006-02-06 2010-02-23 Andrei Volkov Method for analyzing dynamic detectable events at the single molecule level
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
MA49395A (en) 2017-06-14 2020-04-22 Modernatx Inc POLYNUCLEOTIDES COAGULATION FACTOR VIII CODING
EP3714045A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
EP3714047A2 (en) 2017-11-22 2020-09-30 ModernaTX, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
EP3714048A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US20210163928A1 (en) 2018-04-11 2021-06-03 Modernatx, Inc. Messenger rna comprising functional rna elements
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (en) 2018-09-02 2021-07-14 Modernatx Inc POLYNUCLEOTIDES ENCODED FOR VERY LONG CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY
US20220243182A1 (en) 2018-09-13 2022-08-04 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
MX2021003015A (en) 2018-09-13 2021-07-15 Modernatx Inc Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease.
CA3112398A1 (en) 2018-09-14 2020-03-19 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
CN114375190A (en) 2019-05-08 2022-04-19 阿斯利康(瑞典)有限公司 Compositions for skin and wounds and methods of use thereof
MA56517A (en) 2019-06-24 2022-04-27 Modernatx Inc MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS AND THEIR USES
EP4045076A1 (en) 2019-10-15 2022-08-24 ModernaTX, Inc. Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
AU2020368447A1 (en) 2019-10-15 2022-04-28 Modernatx, Inc. mRNA encoding immune modulating polypeptides and uses thereof
JP2023510308A (en) 2020-01-10 2023-03-13 モデルナティエックス インコーポレイテッド Methods of making tolerogenic dendritic cells
CA3168945A1 (en) 2020-01-30 2021-08-05 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
EP4149435A1 (en) 2020-05-14 2023-03-22 Modernatx, Inc. Lnp compositions comprising an mrna therapeutic and an effector molecule
WO2021247507A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
JP2023531511A (en) 2020-06-23 2023-07-24 モダーナティエックス・インコーポレイテッド LNP compositions comprising mRNA therapeutics with extended half-lives
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
EP4314260A1 (en) 2021-03-24 2024-02-07 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023196399A1 (en) 2022-04-06 2023-10-12 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
ES2173082T3 (en) * 1991-08-07 2002-10-16 W French Anderson RETROVIRAL VECTORS CONTAINING INTERNAL RIBOSOME ENTRY SITES.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Registry File, Registry No. 154451-13-5 *
DNA Cell Biology 1993,12(10),881-892 *
J.Mol.Biol. 1993,231,155-158 *
Proc.Natl.Acad.Sci.USA 1991,88,10114-10118 *

Also Published As

Publication number Publication date
WO1995014775A1 (en) 1995-06-01
GB9424130D0 (en) 1995-01-18
AU1074495A (en) 1995-06-13
GB2284210B (en) 1997-11-12
JPH09505474A (en) 1997-06-03
US5723332A (en) 1998-03-03
AU692196B2 (en) 1998-06-04
CA2174863A1 (en) 1995-06-01
EP0730645A1 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
US5723332A (en) Translational enhancer DNA
JP3966903B2 (en) Hamster's powerful homologous promoter
Shalloway et al. Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells.
KR100379356B1 (en) DNA constructs and their uses to achieve homologous recombination
JPH11502122A (en) Protein production and transport
JP3073009B2 (en) Recombinant DNA method and vector used therefor
US20100120089A1 (en) A novel vector and expression cell line for mass production of recombinant protein and a process of producing recombinant protein using same
JP2000513948A (en) Hamster EF-1α transcription regulatory DNA
EP0516787B1 (en) Expression systems
AU5494699A (en) Episomally relicating vector, its preparation and use
US5981224A (en) Bovine heat shock promoter and uses thereof
KR0142675B1 (en) Gene expression regulator
US5912168A (en) CD95 regulatory gene sequences
ZA200005746B (en) Modifying the expression of the FSH beta gene by homologous recombination.
US20030232414A1 (en) Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
JP2002537807A (en) Regulatory construct containing intron 3 of prostate specific membrane antigen gene
JPH10500848A (en) Nucleic acid sequence controlling lung cell-specific gene expression
US7868154B2 (en) Promoter to IL-18BP, its preparation and use
JP2905506B2 (en) Gene expression regulator
US5534631A (en) Cellular factor ILF
KR19990072793A (en) Adenoviral transfer vector for the gene transport of a DNA sequence
JP2007530009A (en) Method for producing a polypeptide
WO1994016062A1 (en) Complement regulatory proteins of herpesvirus saimiri
WO1992006195A1 (en) Dna and amino acid sequence specific for natural killer cells and t cells
JP2002511254A (en) Herpes simplex virus latency-related transcript polypeptides

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19991125